Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
Read More
3 minute read

National Institute on Drug Abuse Will Test Ibogaine For Addiction Treatment As Drug Deaths Crest 100,000

By David E. Carpenter
Today, 3:56 PM
The U.S. government has taken a significant step toward tackling the mounting national substance addiction crisis by partnering with neuroscience company Delix Therapeutics to study a non-hallucinogenic version of the psychedelic drug ibogaine.  

ATAI

Read More
2 minute read

New York City Conference ‘Horizons: Perspectives on Psychedelics’ A Who’s Who Of Notable Speakers

By David E. Carpenter
Today, 3:56 PM
In a welcomed throwback to the days before psychedelic use and research was considered a forbidden topic, the conference “Horizons: Perspectives On Psychedelics” in New York City is an incredible testimony to where the field of psychedelic therapy, and the industry as a whole, is

CMPS

Read More
2 minute read

Novamind Partners With Bienstar Wellness, Opening Door To Ibogaine Treatment For Addiction Disorders

By David E. Carpenter
Today, 3:56 PM
Novamind Inc. (OTCQB: NVMDF) a mental health company specializing in psychedelic medicine, recently announced a strategic investment and advisory agreement with Bienstar Wellness Corp, an Uruguay-based mental health company, to assist in the expansion of Latin Ameri

NVMDF

Read More
3 minute read

Psilocybin Trials For COVID-Related Distress Of Healthcare Professionals Could Validate New Psychotherapy Model

By David E. Carpenter
Today, 3:56 PM
Cybin (NYSE: CYBN), a biotech company focused on progressing psychedelic therapeutics, has announced that the FDA has given them authorization for Phase 2 clinical trials evaluating psychedelic-assisted psychotherapy with psilocybin for frontline clinicians experiencing COVID-related distress

CYBN